EF Hutton analyst Tim Moore assumed coverage of Hoth Therapeutics with a Buy rating and $14 price target. The firm made no change to its prior rating, price target or estimates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HOTH: